A Phase III, Randomized, Open-label, Active-Controlled, Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Hemoglobin changes
No
United States: Food and Drug Administration
AMAG-FER-IDA-302
NCT01114204
June 2010
June 2012
Name | Location |
---|---|
AMAG Pharmaceuticals, Inc. | Lexington, Massachusetts 02421 |